Medacta reports 9.7% revenue growth in first half of 2026

Medacta, the Swiss medical device maker, reported revenue growth of 9.7% on a constant-currency basis for the first half of 2026, buoyed by solid performance in Asia Pacific and EMEA.

The company's adjusted EBITDA margin for the first half reached 27.8% in constant currency, while adjusted EBITDA totaled €97 million. Net profit declined relative to the prior-year period because of a one-off gain recorded in 2025.

Revenue growth was driven by double-digit increases across Asia Pacific and EMEA, whereas North America recorded slower expansion, weighed down by a softer U.S. market and a sales channel transition in the Spine segment.

The Hip, Knee and Extremities segments expanded on the strength of new technology platforms, including the AMIS approach, NextAR augmented-reality navigation and GMK SpheriKA implants. Medacta also reported higher revenue from new surgeon activity in all business lines, especially in U.S. ambulatory surgery centers and academic centers.

For full-year 2026, Medacta is targeting revenue growth of 10% to 14% in constant currency. The company also expects its adjusted EBITDA margin to improve by about 50 basis points compared with the prior year.

Medacta projects a revenue compound annual growth rate of 12% to 15% in constant currency for the 2024-2027 period.

This article was created with AI support and subsequently reviewed by an editor. For more information, please refer to our Terms & Conditions.